The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2025

Filed:

Feb. 11, 2019
Applicant:

The Trustees of Dartmouth College, Hanover, NH (US);

Inventors:

Charles Sentman, Grantham, NH (US);

David Graber, Hanover, NH (US);

W. James Cook, Hanover, NH (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/414 (2025.01); A61K 40/416 (2025.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C12N 5/0637 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present disclosure generally relates to novel chimeric antigen receptors ('CARs'), modified regulatory T cells (“Tregs”) expressing such CARs and/or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative/inflammatory activity, or which promote neuronal growth/survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and/or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.


Find Patent Forward Citations

Loading…